Impact News +++ Multitude AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with... (GlobeNewswire EN) +++ MULTITUDE AG Aktie +6,67%

Gewinn & Umsatz News zur DAIICHI SANKYO Aktie

>DAIICHI SANKYO Aktienkurs

14.28 EUR +3.0% (TradegateBSX)

Ask: 14.288 EUR / 349 Stück

Bid: 14.136 EUR / 354 Stück

Tagesumsatz: 2914 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>DAIICHI SANKYO Performance

1 Woche: +0,5%

1 Monat: -3,3%

3 Monate: -10,8%

6 Monate: -22,7%

1 Jahr: -29,3%

laufendes Jahr: -24,8%

>DAIICHI SANKYO Aktie

Name:

DAIICHI SANKYO CO. LTD

Land:

Japan

Sektor:

Gesundheit

ISIN/ Wkn:

JP3475350009 / A0F57T

Symbol/ Ticker:

D4S (Frankfurt)

Kürzel:

FRA:D4S, ETR:D4S, D4S:GR

Index:

Nikkei225

Webseite:

https://www.daiichisankyo..

Profil:

Daiichi Sankyo Co., Ltd. is a Japan-based pharmaceutical company specializing in the research, development, and commercialization of innovative medicines. Formed in 2005 through the merger of Daiichi Pharmaceutical and Sankyo, the company focuses pri..
>Volltext..

Marktkapitalisierung:

25042.38 Mio. EUR

Unternehmenswert:

24499.25 Mio. EUR

Umsatz:

11745.38 Mio. EUR

EBITDA:

1663.97 Mio. EUR

Nettogewinn:

1437.71 Mio. EUR

Gewinn je Aktie:

0.78 EUR

Schulden:

1936.6 Mio. EUR

Liquide Mittel:

1469.96 Mio. EUR

Operativer Cashflow:

429.61 Mio. EUR

Bargeldquote:

0.51

Umsatzwachstum:

-0.43%

Gewinnwachstum:

-22.27%

Dividende je Aktie:

0.44 EUR

Dividendenrendite:

3.04%

Dividendenschätzung:

Div. Historie:

30.03.26 - 0.21295445€
29.09.25 - 0.2222064€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

DAIICHI SANKYO

Letzte Datenerhebung:

29.06.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 1819.65 Mio. St.

Frei handelbar: 86.44%

Leerverk. Aktien: -

Rückkaufquote: 3.32%

Mitarbeiter: 20171

Umsatz/Mitarb.: 0.58 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 66.71%

Bewertung:

KGV: 17.75

KGV lG: 15.27

KUV: 2.19

KBV: 2.72

PEG-Ratio: -

EV/EBITDA: 14.72

Rentabilität:

Bruttomarge: 68.49%

Gewinnmarge: 12.24%

Operative Marge: 9.76%

Managementeffizenz:

Gesamtkaprendite: 6.97%

Eigenkaprendite: 15.81%

>Peer Group

Gesundheit, Antikörper- Behandlung, Onkologie/ Krebs- Behandlung, Herz-Kreislauf- Behandlung/ Kardiologie

>DAIICHI SANKYO Chart & Kurs - Tradegate

>DAIICHI SANKYO Gewinn & Umsatz News

11.05.26 - 10:42	Daiichi Sankyo Unveils Five-year Plan Targeting 2.3 Tln Yen Oncology Revenue By 2030 (AFX)
	TOKYO (dpa-AFX) - Daiichi Sankyo Company Limited (DSKYF) on Monday unveiled its new five-year business plan for fiscal 2026-2030, targeting oncology revenue of more than 2.3 trillion yen by 2030 a......

11.05.26 - 10:00	Daiichi Sankyo Expects Annual Results To Improve On Higher Enhertu, Datroway Sales (AFX)
	TOKYO (dpa-AFX) - Daiichi Sankyo Company Limited (DSKYF, 4568.T), a Japanese pharmaceutical company, said on Monday that it expects a rise in earnings and revenue for the full year, supported by i......

11.05.26 - 09:36	Daiichi Sankyo Earnings Fall; Guides FY27 (AFX)
	TOKYO (dpa-AFX) - Daiichi Sankyo Co. Ltd. (DSKYF, 4568.T, DSNKY), a Japanese pharmaceutical company, on Monday reported lower net income in the full year ended March 31, 2026 compared with the pre......

11.05.26 - 09:12	Daiichi Sankyo Company Limited Profit Retreats In Full Year (AFX)
	TOKYO (dpa-AFX) - Daiichi Sankyo Company Limited (DSKYF) announced earnings for full year that Dropped, from the same period last yearThe company's bottom line came in at JPY259.874 billion, or JP......

24.04.26 - 05:09	Daiichi Sankyo shares slide to 4-yr low after co delays annual earnings (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

24.04.26 - 03:06	Daiichi Sankyo Shares Fall After Earnings Announcement Delayed (Bloomberg)
	Daiichi Sankyo Co. shares fell the most in more than 18 months after the pharmaceutical company delayed releasing earnings as it reviews supply plans for its oncology portfolio and assesses potential loss provisions tied to contract manufacturing....

31.10.25 - 06:30	Daiichi Sankyo H1 Earnings Down, Cuts FY Earnings View, Lifts Revenue Forecast; Stock Down (AFX)
	TOKYO (dpa-AFX) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) on Friday trimmed its earnings forecast for full-year ending March 31, 2026, after reporting weak profit in its first ......

08.09.25 - 07:42	Daiichi Sankyo And Merck: Ifinatamab Deruxtecan Shows Promising Results In Phase 2 ES-SCLC Trial (AFX)
	KENILWORTH (NJ) (dpa-AFX) - Daiichi Sankyo (DSKYF, 4568.T) and Merck & Co Inc. (MRK) announced that Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstra......

31.07.25 - 12:24	Daiichi Sankyo Q1 Profit Edges Up, Revenues Rise; Confirms FY Outlook (AFX)
	TOKYO (dpa-AFX) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) reported Thursday first-quarter profit attributable to shareholders of 85.50 billion Japanese yen, up 0.1 percent from......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer zuviel lernen will, der lernt nichts. - Sprichwort Deutschland

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram